表紙
市場調查報告書

帕金森氏症治療藥的全球市場 - 成長率,趨勢及預測(2019年∼2024年)

Parkinson's Disease Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 391455
出版日期 內容資訊 英文 111 Pages
商品交期: 2-3個工作天內
價格
Back to Top
帕金森氏症治療藥的全球市場 - 成長率,趨勢及預測(2019年∼2024年) Parkinson's Disease Drugs Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年03月01日內容資訊: 英文 111 Pages
簡介

帕金森氏症是一種慢性疾病,由多巴胺產生腦細胞的喪失,逐漸導致運動功能的進行性惡化。 由於帕金森氏症病例的增加,人口老齡化水平的增加,預計帕金森氏症藥物市場將出現顯著成長。因此可能會在預測期間大幅增加市場規模。製藥公司為帕金森氏症(PD)開發新的和改進療法,最近,帕金森氏症治療和其他輔助療法已經出現了一些主要產品。例如,Adamas Pharmaceuticals的金剛烷胺緩釋膠囊/ Gocovri於2018年1月推出,這是第一種因長期使用左旋多巴而出現運動障礙的藥物。此外,大多數全球公司都擁有用於治療帕金森氏症的強大藥物管道,並且根據估計,預測期可能會出現一些重量級藥物。

本報告提供全球帕金森氏症治療藥市場調查,整體市場趨勢,各產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等資訊彙整。

目錄

第1章 簡介

  • 調查的成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 老年人口的增加
    • 最新醫藥品核准
    • 疾病的認識高漲
  • 市場阻礙因素
    • 對主要的治療方法的學名藥競爭
    • 治療費用高
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭激烈度

第5章 市場區隔

  • 各作用機制
    • 多巴胺促效劑
    • 抗膽鹼促效劑
    • MAO-B抑制劑
    • Amantadine
    • Carbidopa-levodopa
    • COMT抑制劑
    • 其他作用機制
  • 地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Merck & Co. Inc.
    • Impax Laboratories Inc.
    • AbbVie Inc.
    • Mylan NV
    • Boehringer Ingelheim
    • GlaxoSmithKline plc
    • M Somerset Pharmaceuticals Inc.
    • Teva Pharmaceuticals Industries Ltd
    • Pfizer Inc.
    • Novartis AG

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 48146

Market Overview

Parkinson's disease is a chronic disorder that gradually leads to progressive deterioration of motor functions, caused by the loss of dopamine-producing brain cells. Parkinson's disease drugs market is expected to witness significant growth, owing to the increasing cases of Parkinson's disease, with the growth in aging population levels. Therefore, it may drastically result in increasing the market size during the forecast period. Pharmaceutical firms are developing new and improved therapies for Parkinson's disease (PD), and recently, there have been some major product launches in Parkinson disease therapeutics and other assistive therapeutics. For instance, Adamas Pharmaceuticals' amantadine extended-release capsules / Gocovri launched in Jan 2018, which was the first drug indicated for dyskinesia developed due to long-term use of levodopa. Furthermore, most of the global firms have a robust drug pipeline for the treatment of Parkinson's disease, and as per the estimates, the forecast period may witness the launch of a few blockbuster drugs.

Scope of the Report

Parkinson's disease drugs market has been segmented by the mechanism of action and geography. BY mechanism of action, the market studied is segmented into dopamine agonists, anticholinergic, MAO-B inhibitors, amantadine, carbidopa-levodopa, COMT inhibitors, and other mechanisms of action. By geography, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East & Africa.

Key Market Trends

COMT (Catechol-O-Methyltransferase) Inhibitors are expected to Register Robust growth

Carbidopa-levodopa Therapy is the most effective medication for alleviating the motor symptoms of PD. However, it has been observed that this medication is not as effective as intended. Therefore, it is imperative that co-therapeutic agents, such as COMT (catechol-O-methyltransferase) inhibitors, are used along with carbidopa-levodopa therapy. The two most common COMT inhibitors, used in the treatment of Parkinson's disease, are Comtan (entacapone) and Tasmar (tolcapone). Both these medications are available in the form of tablets. In addition, these medications are routinely prescribed in conjunction with carbidopa-levodopa therapy.

The United States Represents the Largest Market for Parkinson's Disease Therapeutics

According to the National Institute of Health, approximately 1.2 million people in the United States are predicted to have Parkinson's disease by 2030. It is the second-most common neurodegenerative disorder in the United States. In addition, there are thousands of patients who go undetected. As the aging population levels continue to grow, the number of people suffering from Parkinson's disease (PD) will continue to grow, and this is expected to double by 2040. The sheer number of Parkinson's disease patients, combined with the availability of reimbursements and high awareness, is boosting the growth of the market. Furthermore, the high cost of Parkinson's disease therapeutics in the United States also leads to significant market size in terms of revenue. The average cost of Parkinson's medication is approximately USD 2,500 per year and Parkinson's-related surgery can cost up to USD 100,000 per patient.

Competitive Landscape

Parkinson's disease drugs market is becoming highly competitive. The recent product launches and the high number of therapeutics in product pipelines of global pharmaceutical firms are contributing to the dynamic nature of the market. Several new product launches are expected during the forecast period, which may lead to significant changes in market shares of pharmaceutical firms currently active in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Geriatric Population
    • 4.2.2 Recent Drug Approvals
    • 4.2.3 Growing Awareness
  • 4.3 Market Restraints
    • 4.3.1 Generic Competition to Key Therapies
    • 4.3.2 High Cost of Treatment
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Mechanism of Action
    • 5.1.1 Dopamine Agonists
    • 5.1.2 Anticholinergic
    • 5.1.3 MAO-B inhibitors
    • 5.1.4 Amantadine
    • 5.1.5 Carbidopa-levodopa
    • 5.1.6 COMT Inhibitors
    • 5.1.7 Other Mechanisms of Action
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 US
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 UK
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East & Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East & Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Merck & Co. Inc.
    • 6.1.2 Impax Laboratories Inc.
    • 6.1.3 AbbVie Inc.
    • 6.1.4 Mylan NV
    • 6.1.5 Boehringer Ingelheim
    • 6.1.6 GlaxoSmithKline plc
    • 6.1.7 M Somerset Pharmaceuticals Inc.
    • 6.1.8 Teva Pharmaceuticals Industries Ltd
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Novartis AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top